Creative Medical Technology Holdings, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Creative Medical Technology Holdings, Inc. (CELZ) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 176.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-20
- Creative Medical Technology Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, percent for the quarter ending 2025-03-31 was 166.00%, a 78.59% increase year-over-year.
- Creative Medical Technology Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, percent for the quarter ending 2024-03-31 was 92.95%, a 0.00% change year-over-year.
- Creative Medical Technology Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, percent for the quarter ending 2023-03-31 was 92.95%.
- Creative Medical Technology Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was 176.00%, a 0.00% change from fiscal 2024.
- Creative Medical Technology Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was 176.00%, a 89.35% increase from fiscal 2023.
- Creative Medical Technology Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was 92.95%, a 0.00% change from fiscal 2022.
- Creative Medical Technology Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was 92.95%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 0 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 1 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | 176.00% 10-K · filed 2026-03-20 | |||||
| 2025-10-29 | 147.00% 10-K · filed 2026-03-20 | |||||
| 2025-06-30 | 166.00% 10-Q · filed 2025-08-08 | |||||
| 2025-03-31 | 166.00% 10-Q · filed 2025-05-09 | |||||
| 2025-03-06 | 166.00% 10-K · filed 2026-03-20 | |||||
| 2024-12-31 | 176.00% 10-K · filed 2025-03-14 | |||||
| 2024-09-30 | 92.95% 10-Q · filed 2024-11-08 | |||||
| 2024-06-30 | 92.95% 10-Q · filed 2024-08-09 | |||||
| 2024-03-31 | 92.95% 10-Q · filed 2024-05-10 | |||||
| 2023-12-31 | 92.95% 10-K · filed 2024-03-22 | |||||
| 2023-09-30 | 92.95% 10-Q · filed 2023-11-14 | |||||
| 2023-06-30 | 92.95% 10-Q · filed 2023-08-11 | |||||
| 2023-03-31 | 92.95% 10-Q · filed 2023-05-12 | |||||
| 2022-12-31 | 92.95% 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |